The EPS projection of Seattle Genetics, Inc. (NASDAQ:SGEN) for quarter ended 2016-09-30 is $-0.32. Last week, the EPS forecast was $-0.32 against target of $-0.32, a month earlier. Two months ago, this estimate was $-0.32 versus forecast of $-0.32 three months earlier, implying a deviation of 0%.
Seattle Genetics, Inc. (NASDAQ:SGEN) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 3.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 1, and 1, correspondingly.
EPS estimate downgrade for Seattle Genetics, Inc. (NASDAQ:SGEN) in the preceding 30, 120, 60 and 90 days were 0, 6, 6, and 6, correspondingly.
Seattle Genetics, Inc. (NASDAQ:SGEN) EPS target for the quarter closed 1 was $-0.32, based on 9 recommendations. As reported on 2016-04-28 the EPS was $-0.15. The change was $-0.04, implying a percentage deviation of -36.36%. The projections showed a standard deviation of 0.05.
Quarterly Sales Estimates
Seattle Genetics, Inc. (NASDAQ:SGEN) yearly sales prediction for the fiscal 2016 stands at $108.577 and the median estimate is at $107.05. Almost 6 analysts issued sales target.
Highest sales target is $117.563 while the lowest target is $104.3 showing standard deviation of 4.999%.
As many as 6 analysts have sales targets revised upside while 6 reduced sales estimates, implying a deviation of -0.781%.
Last month, 6 revised sales number projection on upside while 6 lowered the sales projections, implying a deviation of -0.781%.
A quarter ago, 6 hiked sales target and 6 reduced sales forecast. Seattle Genetics, Inc. (NASDAQ:SGEN) announced that the deviation in forecast was 1.095%.
1 Chart Pattern Every Investor Should Know